RxDoctor Payments DataLook up a doctor →

Kevin Weibel, DO

Hematology & Oncology · Tulsa, OKNPI 1104864016

Payments from drug & device makers

$1,678,175in general payments, 2019–2025

Across 215 payments — averaging $7805.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.6M
  • Mirati Therapeutics, Inc.$123K
  • Eli Lilly$2K
  • Pfizer$632
  • AstraZeneca$330
  • Astellas Pharma US Inc$187
  • plus $2K from 44 others

What the payments were for

  • Food & beverage$2,71655%
  • Education$77416%
  • Other$1,44629%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,678,175 in reported general payments places this provider in the 95th percentile of 118 hematology & oncology providers in Oklahoma.

See all hematology & oncology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$3,792,571
Medicare patients
945
Services billed
166,880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CabometyxCabozantinib S-Malate19$493,986
IbrancePalbociclib30$461,497
BrukinsaZanubrutinib41$399,457
VenclextaVenetoclax45$358,446
XareltoRivaroxaban17$14,205
Exemestane53$5,740
Tamoxifen Citrate122$3,604
Letrozole148$3,310
Anastrozole183$3,016
Hydroxyurea45$1,390
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen59$1,338
Gabapentin62$924
Ondansetron OdtOndansetron59$833
Dexamethasone32$698
ValacyclovirValacyclovir Hcl17$648

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Exelixis Inc.Cabometyx$70$493,98619 claims
PfizerIbrance$632$461,49730 claims
Beigene USA, Inc.Brukinsa$18$399,45741 claims
AbbVieVenclexta$36$358,44645 claims
Johnson & JohnsonXarelto$73$14,20517 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 118 hematology & oncology providers in Oklahoma.

Other hematology & oncology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →